comparemela.com
  1. Home
  2. Live Updates
  3. President Athena Countouriotis - Breaking News

Latest Breaking News On - President athena countouriotis - Page 1 : comparemela.com

Here is Why Turning Point Therapeutics Jumped 110%

Bristol Myers Squibb has entered a definitive merger agreement to purchase Turning Point for $76 per share

Athena countouriotisGiovanni caforioBristol myersPoint therapeutics incGlobal drug development samit hirawatBristol myers squibbBristol myers squibb coTurning point therapeutics incTurning pointTurning point therapeuticsBreakthrough therapyPresident athena countouriotis

Turning Point Buys Rights to LaNova s Claudin18 2-Targeting Drug

The agent is Turning Point's first in-licensed product, which is currently undergoing early-stage trials in Claudin18.2-positive advanced solid tumors.

South koreaAthena countouriotisTurning point therapeuticsLanova medicine claudinGreater chinaShanghai based lanovaSan diego based turning pointPresident athena countouriotis

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.